Virus-specific cytotoxic T cells in chronic active Epstein-Barr virus infection. 2017

Haruna Shibayama, and Ken-Ichi Imadome, and Erika Onozawa, and Akiho Tsuzura, and Osamu Miura, and Takatoshi Koyama, and Ayako Arai
Department of Hematology, Tokyo Medical and Dental University.

Chronic active Epstein-Barr virus infection (CAEBV) is a disease characterized by clonally proliferating and activated EBV-infected T or NK cells accompanied by chronic inflammation and T- or NK-cell neoplasms. However, the mechanism for developing CAEBV has not been clarified to date. Because the decreased number or inactivation of EBV-specific cytotoxic T lymphocytes (CTLs) resulted in the development of EBV-positive B-cell neoplasms, we investigated the number of CTLs in CAEBV patients using the tetrameric complexes of HLA-restricted EBV-specific peptides. Among the seven patients examined, EBV-specific CTLs were detected in the peripheral blood mononuclear cells (PBMCs) of four cases but were not detected in three cases. The ratio of EBV-specific CTLs in PBMCs tended to be higher in the patients with active disease than in those with inactive disease. In two patients in whom EBV-specific CTLs had not been detected, CTLs appeared after the eradication of EBV-infected T cells by allogeneic bone marrow transplantation. These results suggested that the failure of CTLs had a role in developing CAEBV, although the induction number and function of EBV-specific CTLs might vary in each patient.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D004854 Herpesvirus 4, Human The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies. Burkitt Herpesvirus,Burkitt Lymphoma Virus,E-B Virus,EBV,Epstein-Barr Virus,Human Herpesvirus 4,Infectious Mononucleosis Virus,Burkitt's Lymphoma Virus,HHV-4,Herpesvirus 4 (gamma), Human,Burkitts Lymphoma Virus,E B Virus,E-B Viruses,Epstein Barr Virus,Herpesvirus, Burkitt,Infectious Mononucleosis Viruses,Lymphoma Virus, Burkitt,Mononucleosis Virus, Infectious,Mononucleosis Viruses, Infectious
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D014775 Virus Activation The mechanism by which latent viruses, such as genetically transmitted tumor viruses (PROVIRUSES) or PROPHAGES of lysogenic bacteria, are induced to replicate and then released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell LIPOPOLYSACCHARIDES, glucocorticoid hormones, halogenated pyrimidines, IONIZING RADIATION, ultraviolet light, and superinfecting viruses. Prophage Excision,Prophage Induction,Virus Induction,Viral Activation,Activation, Viral,Activation, Virus,Activations, Viral,Activations, Virus,Excision, Prophage,Excisions, Prophage,Induction, Prophage,Induction, Virus,Inductions, Prophage,Inductions, Virus,Prophage Excisions,Prophage Inductions,Viral Activations,Virus Activations,Virus Inductions

Related Publications

Haruna Shibayama, and Ken-Ichi Imadome, and Erika Onozawa, and Akiho Tsuzura, and Osamu Miura, and Takatoshi Koyama, and Ayako Arai
March 2003, Deutsche medizinische Wochenschrift (1946),
Haruna Shibayama, and Ken-Ichi Imadome, and Erika Onozawa, and Akiho Tsuzura, and Osamu Miura, and Takatoshi Koyama, and Ayako Arai
February 2002, American journal of clinical pathology,
Haruna Shibayama, and Ken-Ichi Imadome, and Erika Onozawa, and Akiho Tsuzura, and Osamu Miura, and Takatoshi Koyama, and Ayako Arai
April 2006, Clinical immunology (Orlando, Fla.),
Haruna Shibayama, and Ken-Ichi Imadome, and Erika Onozawa, and Akiho Tsuzura, and Osamu Miura, and Takatoshi Koyama, and Ayako Arai
December 2002, Blood,
Haruna Shibayama, and Ken-Ichi Imadome, and Erika Onozawa, and Akiho Tsuzura, and Osamu Miura, and Takatoshi Koyama, and Ayako Arai
January 2000, Current opinion in hematology,
Haruna Shibayama, and Ken-Ichi Imadome, and Erika Onozawa, and Akiho Tsuzura, and Osamu Miura, and Takatoshi Koyama, and Ayako Arai
August 1987, JAMA,
Haruna Shibayama, and Ken-Ichi Imadome, and Erika Onozawa, and Akiho Tsuzura, and Osamu Miura, and Takatoshi Koyama, and Ayako Arai
October 2020, Blood,
Haruna Shibayama, and Ken-Ichi Imadome, and Erika Onozawa, and Akiho Tsuzura, and Osamu Miura, and Takatoshi Koyama, and Ayako Arai
December 2011, Uirusu,
Haruna Shibayama, and Ken-Ichi Imadome, and Erika Onozawa, and Akiho Tsuzura, and Osamu Miura, and Takatoshi Koyama, and Ayako Arai
December 2013, Human pathology,
Haruna Shibayama, and Ken-Ichi Imadome, and Erika Onozawa, and Akiho Tsuzura, and Osamu Miura, and Takatoshi Koyama, and Ayako Arai
September 2004, The Journal of infectious diseases,
Copied contents to your clipboard!